An experimental drug for multiple sclerosis (MS) that was approved in 2004, then abruptly yanked off shelves last year because of safety concerns, may get a second chance.
Two studies show that the drug can curb MS symptoms and slow progression of the autoimmune disease over 2 years, the longest tests of this drug to date. A third investigation finds no further cases of the often-fatal complication that sidetracked the drug last year, beyond the three patients who fell ill at that time. All three papers appear in the March 2 New England Journal of Medicine.
Note: To comment, Science News subscribing members must now establish a separate login relationship with Disqus. Click the Disqus icon below, enter your e-mail and click “forgot password” to reset your password. You may also log into Disqus using Facebook, Twitter or Google.